Fig. 2: The combination effect of HSV-1 and IDO1 inhibitor Navoximod.

a–c Hepa1-6 cells transfected with empty vector (VT) or Flag-tagged IDO1 construct were infected with HSV-1 for 24 h. a Western blotting analysis of gD, FLAG and GAPDH. b RT-qPCR analysis of gD (left) and ICP47 (right) DNA level (n = 3; Data were shown as means ± SEM). c Representative fluorescence imaging (left) and flow cytometry analysis (right) of GFP-positive Hepa1-6 cells. Scale bar: 100 μm. n = 3. Data were shown as means ± SEM. d IDO1 expression in HCCs and their corresponding peri-tumor tissues was determined by TCGA HCC cohort (left) and transcriptome sequencing (right). Data were shown as means ± SEM. e Hepa1-6 cells infected with 20 MOI HSV-1 for 12 h were analyzed by RT-qPCR for IDO1 mRNA level (n = 3; Data were shown as means ± SEM). f, g Hepa1-6 cells were treated with 5 MOI HSV-1 or 5 MOI HSV-1 plus 1 μM Navoximod (V-Navo). f RT-qPCR analysis of gD (left) and ICP47 (right) DNA level at the indicated time points (n = 3; Data were shown as means ± SEM). g Western blotting analysis of gD and GAPDH. h Cell viability of Hepa1-6 cells with indicated treatments was determined by flow cytometry analysis using Annexin V-APC and PI staining (n = 2; Data were shown as means ± SEM). i RT-qPCR analysis of the intratumoral HSV-1 genomic DNA levels represented by gD (left) and ICP47 (right) 8 days after the indicated treatments (n = 7; Data were shown as means ± SEM).